|
TW202017600A
|
|
Composition containing a somatostatin analogue for radiopharmaceutical use
|
|
TW202015744A
|
|
Composition containing a somatostatin analogue for radiopharmaceutical use
|
|
EP3067062A1
|
|
Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
|
|
CN105143232A
|
|
Macrocyclic IRRK2 kinase inhibitors
|
|
EP2961786A1
|
|
Novel method for purifying polyesters
|
|
EP3089975A1
|
|
Novel imidazolidine-2, 4-dione derivatives
|
|
CN104768565A
|
|
Somatostatin analogs and dimers thereof
|
|
TW201422636A
|
|
Somatostatin-dopamine chimeric analogs
|
|
EP2832361A1
|
|
Aqueous sustained release compositions of LHRH analogs
|
|
EP2823808A1
|
|
Pharmaceutical composition for a sustained release of lanreotide
|
|
AU2013201451A1
|
|
Method for inhibiting inflammation and pre-inflammatory cytokine/chemokine expression using a ghrelin analogue
|
|
WO2014077801A1
|
|
Purification process for preparing highly pure taspoglutide
|
|
CN104936610A
|
|
Purification method of GLP-1 analogue
|
|
CN104023728A
|
|
Macrocyclic lrrk2 kinase inhibitors
|
|
AU2012270024A1
|
|
A sustained -release composition containing a melanocortin receptor ligand as the active ingredient
|
|
EP2705835A1
|
|
Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
|
|
AU2012201490A1
|
|
Method of drug delivery for bone anabolic protein
|
|
EP2606908A1
|
|
Novel pharmaceutical composition for a long acting growth hormone fusion protein (LAGH)
|
|
WO2012084754A2
|
|
Pharmaceutical glp-1 compositions having an improved release profile
|
|
CN107641195A
|
|
The method for preparing star polymer
|
